Quote:

---

MASH competition - AKRO - liver fibrosis reduced in phase 2b results

---

Their drug efruxifermin is a mimic of FGF21. FGF21 degrades fatty acids and reduces conversion and storage in white fat cells. I haven't ran across any studies looking at FGF21 and CCR5 interaction when I looked at another FGF21 drug awhile back. However mTORc1 downregulation increases FGF21 and FGF21 uses AMPK to achieve it's function of non-storage of fat. Leronlimab downregulates mTORc1 and upregulates AMPK. The FGF21 pathway involves both ERK 1/2 and MAPK which seems confounding since leronlimab downregulates both but the actions in both are not a complete blockade so FGF21 activities may not suffer.